Wednesday, July 8, 2026

Drug profile · INN

metyrapone

metyrapone (METOPIRONE) is a cytochrome p450 11b1, mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — metyrapone
US status
approved
Class
Route
ORAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

metyrapone (METOPIRONE) is a cytochrome p450 11b1, mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN metyrapone
Brand METOPIRONE
Mechanism Cytochrome P450 11B1, mitochondrial inhibitor
Target Cytochrome P450 11B1, mitochondrial
Route ORAL
Formulation CAPSULE

Mechanism of action

Cytochrome P450 11B1, mitochondrial inhibitor

Primary target: Cytochrome P450 11B1, mitochondrial

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. APHP211003 Phase 3 · PARItec · Primary Bilateral Macronodular Adrenal Hyperplasia causing m
  2. metyrapone & oxazepam Phase 1 · BRIGHT MINDS BIOSCIENCES · Cocaine Use Disorder

Related & competitor drugs

  1. osilodrostat phosphate Cytochrome P450 11B1 inhibitor

Frequently asked questions

What is metyrapone?

metyrapone (METOPIRONE) is a cytochrome p450 11b1, mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for metyrapone?

METOPIRONE is a marketed brand name for metyrapone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of metyrapone?

metyrapone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.